ArticleJournal for immunotherapy of cancer2022

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.

Julia Moreno-Vicente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.